Reducing the immune response to immunotoxin.

@article{Frankel2004ReducingTI,
  title={Reducing the immune response to immunotoxin.},
  author={Arthur E Frankel},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 1 Pt 1},
  pages={
          13-5
        }
}
Immunotoxins are hybrid proteins composed of peptide cytotoxins covalently linked to target cell-selective peptide ligands such as monoclonal antibodies, antibody fragments, growth factors, or cytokines. Immunotoxins have been synthesized that kill cells selectively in tissue culture with great 

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.

  • Toxicological sciences : an official journal of the Society of Toxicology
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 2 EXCERPTS

Rituximab delays human anti-toxoin antibody onset: phase I study of SGN-10 (BR96 sFv-PE40) in patients with advanced stage carcinoma

M. N. Saleh, M. Bookman, +13 authors A. LoBuglio
  • Proc. Am. Soc. Clin. Oncol.,
  • 2002
VIEW 2 EXCERPTS